ArticlePediatric research2026
Clinical characteristics and outcomes of pediatric paroxysmal nocturnal hemoglobinuria in Egypt: a real-world cohort study including ravulizumab.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParoxysmal nocturnal hemoglobinuria (PNH) in children is uncommon and often diagnosed late, particularly in resource-limited settings.
methodsWe report our experience with eight Egyptian children diagnosed between 2018 and 2025, highlighting their clinical course and our initial use of ravulizumab.
resultsThe mean age at diagnosis was 12.6 ± 2.8 years, and the median delay before diagnosis was over 1 year. Six patients presented with classic PNH one of whom later evolved to hypocellularity while two demonstrated aplastic anemia -PNH overlap. All presented with severe anemia (mean hemoglobin 6.1 ± 0.9 g/dL), and most had additional cytopenias and biochemical evidence of hemolysis. The disease burden was substantial: thrombotic events, hypertension, and renal involvement were observed during follow-up. Mortality was high; one child died after stem cell transplantation due to acute graft-versus-host disease, and four others, including those with concomitant aplastic anemia died before transplantation could be performed. In contrast, the two patients who received ravulizumab showed rapid clinical and hematologic improvement, became transfusion independent, and experienced only transient adverse effects.
conclusionOur findings underscore the severity of pediatric PNH and highlight the critical importance of timely diagnosis and access to complement inhibition therapy. Ravulizumab demonstrated clear clinical efficacy. IMPACT: Pediatric paroxysmal nocturnal hemoglobinuria (PNH) in Egypt is associated with delayed diagnosis, severe cytopenias, and high early mortality. This study provides rare real-world data from a resource-limited setting with limited access to complement inhibition therapy. Early experience with ravulizumab demonstrated rapid hematologic improvement and transfusion independence. Improving early recognition and access to targeted therapy may reduce morbidity and mortality in affected children.
Identifiers
42332246What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.